中国肿瘤临床与康复

参考文献

[1] Momenimovahed Z,Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world[J]. Breast cancer,2019,11:151-164.

[2] Ferrara N,Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells[J]. Biochem Biophys Res Commun, 1989, 161:851-858.

[3] Bender RJ,Mac Gabhann F. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis[J]. BMC systems biology,2015,9:55.

[4] Yang X,Zhu H,Ge Y,et al. Melittin enhances radiosensitivity of hypoxic head and neck squamous cell carcinoma by suppressing HIF-1a[J]. Tumour biolo,2014,35:10443-10448.

[5] Cheng CC,Guan SS,Yang HJ,et al. Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated vegf release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer[J]. J biomed sci, 2016,23:18.

[6] Kontomanolis EN,Kalagasidou S,Pouliliou S,et al. The notch pathway in breast cancer progression[J]. Scientific World J,2018,2018:2415489.

[7] Rotllan N,Wanschel AC,Fernandez-Hernando A,et al. Genetic evidence supports a major role for akt1 in vsmcs during atherogenesis[J]. Circ res,2015,116:1744-1752.

[8] Chen J,Fu Y,Day DS,et al. Vegf amplifies transcription through ets1 acetylation to enable angiogenesis[J]. Nat commun,2017,8:383.

[9] Wang S,Chen J,Garcia SP,et al. A dynamic and integrated epigenetic program at distal regions orchestrates transcriptional responses to vegfa[J]. Genome res,2019,29:193-207.

[10]阎红琳，吴昊，高利昆，等.乳腺癌组织中cd68、vegf的表达变化及意义[J]．山东医药，2017,57:9-12.

[11]杨虹，曾福仁，刘剑仑，等. ER、PR、HER-2、Ki-67与乳腺癌新辅助化疗疗效相关性分析[J]．中国现代医学杂志，2016,26:54-57.

[12] Tammela T,Alitalo K. Lymphangiogenesis:molecular mechanisms and future promise[J]. Cell,2010,140:460-476.

[13] Oh N,Park JI,Park JH,et al. The role of elk3 to regulate peritumoral lymphangiogenesis and vegf-c production in triple negative breast cancer cells[J]. Biochem biophys res commun,2017,484:896-902.

[14] Wang QS,He R,Yang F,et al. Foxf2 deficiency permits basallike breast cancer cells to form lymphangiogenic mimicry by enhancing the response of vegf-c/vegfr3 signaling pathway[J].Cancer letters,2018,420:116-126.

[15]尹培，曹莉明，游志鑫，等.乳腺癌前哨淋巴结中血管内皮生长因子在不同检查方法的表达及临床意义[J]．临床误诊误治，2017,30:97-100.

[16]罗国庆，周晶晶，李关杰，等.应用小分子干扰rna技术以慢病毒为载体抑制乳腺癌淋巴管生成因子vegf-c的实验研究[J]．中国现代医药杂志，2018,20:17-21.

[17] Zhang Y,Liu J,Lin J,et al. The transcription factor gata1 and the histone methyltransferase set7 interact to promote vegf-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer[J]. Oncotarget,2016,7:9859-9875.

[18] Zajkowska M,Lubowicka E,Malinowski P,et al. Plasma levels of vegf-a,vegf b,and vegfr-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer[J]. Acta Biochim Pol,2018,65:621-628

[19] Maanon J,Perez D,Rhode A,et al. High serum vascular endothelial growth factor c predicts better relapse-free survival in early clinically node-negative breast cancer[J]. Oncotarget,2018,9:28131-28140.

[20]游文锋，许素真，王振彬.乳腺癌患者vegf的表达水平与联合化疗疗效的相关性研究[J]．黑龙江医学，2018,42:524-526.

[21]刘志春，孙景武，杨晓峰.血管内皮生长因子在三阴性乳腺癌中的表达及意义[J]．实用预防医学，2015,22:355-358.

[22] Arai RJ,Petry V,Hoff PM,et al. Serum levels of vegf and mcsf in her2+/her2-breast cancer patients with metronomic neoadjuvant chemotherapy[J]. Biomarker research,2018,6:20.

[23] Lohmann AE,Chia S. Patients with metastatic breast cancer using bevacizumab as a treatment:Is there still a role for it?[J]. Curr Treat Options Oncol,2012,13:249-262.

[24] Incio J,Ligibel JA,McManus DT,et al. Obesity promotes resistance to anti-vegf therapy in breast cancer by up-regulating il-6and potentially fgf-2[J]. Sci Transl Med,2018,10:0945.

[25] Ligibel JA,Alfano CM,Hershman D,et al. Recommendations for obesity clinical trials in cancer survivors:American society of clinical oncology statement[J]. J clin oncol, 2015, 33:3961-3967.

[26] Kiso M,Tanaka S,Saji S,et al. Long isoform of vegf stimulates cell migration of breast cancer by filopodia formation via nrp1/arhgap17/cdc42 regulatory network[J]. Int J cancer,2018,143:2905-2918.

[27] Mackey JR,Ramos-Vazquez M,Lipatov O,et al. Primary results of rose/trio-12,a randomized placebo-controlled phase iii trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer[J]. J Clin Oncol,2015,33:141-148.

[28] Baselga J,Segalla JG,Roche H,et al. Sorafenib in combination with capecitabine:An oral regimen for patients with her2-negative locally advanced or metastatic breast cancer[J]. J Clin Oncol,2012,30:1484-1491.

[29] Choi KH,Jeon JY,Lee YE,et al. Synergistic activity of paclitaxel,sorafenib,and radiation therapy in advanced renal cell carcinoma and breast cancer[J]. Transl oncol, 2019, 12:381-388.

[30] Crown JP,Dieras V,Staroslawska E,et al. Phase iii trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer[J]. J Clin Oncol,2013,31:2870-2878.